EUVIMEDEUVIMED entdecken
Crossref

Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk

Mousumi Bhattacharjee, Avijit Ghosh iD, Shaswati Das, Sushmita Sarker, Saurav Bhattacharya iD, Ankur Das, Subhajit Ghosh, Sreya Chattopadhyay, Swatilekha Ghosh, Arghya Adhikary iD

ACS Biomaterials Science & Engineering · 2024

DOI: 10.1021/acsbiomaterials.4c01081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2024. Verfasst von Mousumi Bhattacharjee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Nanoscience and Nanotechnology, Technology Campus, University of Calcutta, JD-2, Sector-III, Salt Lake, Kolkata, West Bengal 7…. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Breast Neoplasms, Silicon Dioxide. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India, Ministry of AYUSH, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinDrug Resistance, NeoplasmBreast NeoplasmsSilicon DioxideMicroRNAsBenzoquinonesNanoparticlesHumansFemaleCell Line, TumorATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1PorosityDrug CarriersAnimals

Stichwörter der Autor:innen

ABC transporterMDR1Mesoporous silica nanoparticlesMulti drug resistanceTNBCmiR-298

Substanzen

DoxorubicinSilicon DioxidethymoquinoneMicroRNAsBenzoquinonesABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Drug Carriers

Autor:innen und Institutionen

  • Center for Research in Nanoscience and Nanotechnology, Technology Campus, University of Calcutta, JD-2, Sector-III, Salt Lake, Kolkata, West Bengal 700106, India.
  • Department of Physiology, University of Calcutta, 92 Acharya Prafulla Chandra Road, Kolkata, West Bengal 700009, India.
  • Department of Life Science and Biotechnology, Jadavpur University, 188, Raja Subodh Chandra Mallick Rd, Jadavpur, Kolkata, West Bengal 700032, India.
  • Amity Institute of Biotechnology, Amity University, Rajarhat, New Town, Kolkata, West Bengal 700135, India.

ORCID-Profile: Avijit Ghosh, Saurav Bhattacharya, Arghya Adhikary

Förderung

  • Department of Science and Technology, Ministry of Science and Technology, India
  • Ministry of AYUSH, Government of India

Zitieren

APA

Bhattacharjee, M., Ghosh, A., Das, S., Sarker, S., Bhattacharya, S., Das, A., Ghosh, S., Chattopadhyay, S., Ghosh, S., & Adhikary, A. (2024). Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.4c01081

Vancouver

Bhattacharjee M, Ghosh A, Das S, Sarker S, Bhattacharya S, Das A, et al. Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk. ACS Biomaterials Science & Engineering. 2024. doi:10.1021/acsbiomaterials.4c01081

BibTeX
@article{Bhattacharjee2024,
  author = {Bhattacharjee, Mousumi and Ghosh, Avijit and Das, Shaswati and Sarker, Sushmita and Bhattacharya, Saurav and Das, Ankur and Ghosh, Subhajit and Chattopadhyay, Sreya and Ghosh, Swatilekha and Adhikary, Arghya},
  title = {Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2024},
  doi = {10.1021/acsbiomaterials.4c01081}
}
Kostenlos starten →